Data from the phase 2 EV-201 trial supporting a potential expanded FDA approval of enfortumab vedotin (Padcev) in bladder cancer have been published in the Lancet Oncology.1
Specifically, the published data are for cohort 2 of the EV-201 study, in which the antibody-drug conjugate (ADC) enfortumab vedotin was administered to cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior anti–PD-1/PD-L1 therapy. The confirmed objective response rate (ORR) in these patients was 52%.
Based on the results from this cohort, the FDA is currently reviewing a supplemental biologics license applications (sBLA) seeking to expand the approval of the ADC for use in this patient population.
“These patients have few treatment options, and enfortumab vedotin could be a promising new therapy for a patient population with a high unmet need,” lead study author Evan Y. Yu, MD, a professor in the Department of Medicine, Division of Oncology, University of Washington and Fred Hutchinson Cancer Research Center, and coauthors wrote in their study conclusion.
The single-arm, phase 2 EV-201 trial examined enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who had been previously treated with a PD-1/PD-L1 inhibitor, including those who have also been treated with a platinum-containing chemotherapy (cohort 1) and those who have not received a platinum-containing chemotherapy and who are ineligible for cisplatin (cohort 2).
Data for cohort 1 of the trial (n = 128) supported the accelerated approval of enfortumab vedotin. In these patients, the antibody-drug conjugate elicited an ORR of 44%, which included a 12% CR rate, and a 32% partial response rate.
The results for cohort 2 included data from 89 patients. Baseline characteristics showed that patients were a median age of 75, male (74%), and 15% were obese. Two-thirds (67%) of patients exhibited a moderate decrease in kidney function. Looking at the primary site of tumor, 43% had a tumor in the upper tract.
The median time to response was 1.81 months with some patients who have durable responses that extend beyond a year or more. Median DOR was 10.9 months. At a median follow-up of 13.4 months, the median PFS was 5.8 months and median OS was 14.7 months.
In terms of safety, any grade overall TRAEs occurred in 97% of patients and grade 3 or higher TRAEs occurred in 55% of patients. TRAEs led to discontinuations in 16% of patients, and peripheral sensory neuropathy was the most common in 4%. There were 4 deaths that were considered to be treatment related by the investigator and these were a result of acute kidney injury, metabolic acidosis, multiple organ dysfunction syndrome, and pneumonitis.
The FDA is also currently reviewing a separate sBLA that is intended to convert the drug’s accelerated approval into a full approval. This sBLA is based on results from the confirmatory phase 3 EV-301 trial, which were shared during the 2021 Genitourinary Cancers Symposium.2,3 In the study, enfortumab vedotin reduced the risk of death by 30% versus chemotherapy in patients with heavily pretreated locally advanced or metastatic urothelial carcinoma.
The FDA is scheduled to make a decision on the 2 sBLAs on or before August 17, 2021.
Reference
1. Yu EY, Petrylak DP, O'Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial [published online ahead of print May 12, 2021]. Lancet Oncol. doi: 10.1016/S1470-2045(21)00094-2
2. Powles T, Rosenberg JE, Sonpavde G, et al. Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. J Clin Oncol. 2021;39(suppl 6):393. doi: 10.1200/JCO.2021.39.6_suppl.393
3. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. Published online February 12, 2021. N Engl J Med. doi:10.1056/NEJMoa2035807
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Nadofaragene firadenovec shows durable efficacy in NMIBC
April 8th 2024"In this follow-up analysis of the phase 3 study, we demonstrated a sustained response to Adstiladrin treatment over 3 years, allowing more than half of the patients in the study to remain cystectomy free for at least 36 months,” says Colin P.N. Dinney, MD.